Best Chronic Myeloid Leukemia Podcasts (2025)

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

2d ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE 19:46

2d ago19:46

19:46

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: …

1
How I Treat Transfusion Medicine (part 2) 33:57

9d ago33:57

33:57

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George. Find the full published review series in Volume 145 Issue 20 of Blood Journal.By American Society of Hematology

1
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19 ... 20:57

9d ago20:57

20:57

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acut…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

15d ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
How I Treat Transfusion Medicine (part 1) 32:12

16d ago32:12

32:12

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RB…

1
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT 18:15

16d ago18:15

18:15

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differe…

1
Navigating Bladder, Melanoma, and Skin Cancer with Dr. Eanelli 51:11

17d ago51:11

51:11

Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santan…

1
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease 19:58

23d ago19:58

19:58

In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickl…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

26d ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature 18:12

30d ago18:12

18:12

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffu…

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ... 19:06

1M ago19:06

19:06

In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

1M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

1M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
How I Treat Myeloproliferative Neoplasms 38:36

1M ago38:36

38:36

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat se…

1
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL 18:49

1M ago18:49

18:49

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options…

1
Cancer, Siblings, and Jennie Milton's MacGyver Mindset 48:56

2M ago48:56

48:56

On Navigating Cancer TOGETHER, join Talaya Dendy as she welcomes Jennie 'AdrenaJen' Milton (author, snow kiter, and resilience coach). Jennie shares her inspiring family journey with her brother's three-time cancer survival and her struggles overcoming depression and brain aneurysms. Discover her 'MacGyver mindset' for tackling life's challenges an…

1
Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed ... 20:59

2M ago20:59

20:59

In this week's episode we’ll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refract…

1
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL 15:26

2M ago15:26

15:26

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, …

1
The Year I Waited: Understanding Why We Delay Our Health 17:50

2M ago17:50

17:50

Why do we wait? Why do we sometimes ignore those nagging health concerns? Join host Talaya Dendy on Navigating Cancer TOGETHER as she shares her journey of delaying medical attention for a year after a doctor dismissed her initial worries. Discover the relatable reasons behind her hesitation, from the pressures of work and family to the underlying …

1
Blood Bonus Episode: What is a Blood group? 14:59

2M ago14:59

14:59

In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-ne…

1
Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle ... 19:16

2M ago19:16

19:16

In this week's episode, we’ll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles: Itacitinib…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

2M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis 19:07

2M ago19:07

19:07

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome…

1
C.H.L.M.S. Medi-Helpz: Strengthening Healthcare Advocacy 49:23

2M ago49:23

49:23

Ever feel lost in the maze of healthcare? As part of Podcasthon, Talaya Dendy sits down with Sandra Washington in this powerful and special episode. Sandra is the driving force behind C.H.L.M.S. Medi-Helpz, and she shares her incredible journey as a patient, revealing the raw, personal inspiration that sparked her mission to bridge the healthcare g…

1
Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL 21:28

3M ago21:28

21:28

In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL. Featu…

1
Navigating Cancer Shock: Tips for Immediate Self-Care 27:14

3M ago27:14

27:14

In this episode of Navigating Cancer TOGETHER, host Talaya Dendy continues her personal story, sharing her initial reactions to being diagnosed with stage three Hodgkin's lymphoma. Talaya recounts the emotional journey following a devastating phone call on a Friday evening, the impact it had on her weekend, and the steps she took to calm herself an…

1
Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk 17:48

3M ago17:48

17:48

In this week's podcast, a potential new therapeutic target in beta-thalassemia. The E3 ubiquitin ligase AMBRA1 promotes autophagic clearance of free alpha-globin. Researchers describe mutations in the AMBRA1 gene that impair this clearance, exacerbating ineffective erythropoiesis and disease severity. After that: targeting MYD88 mutations. Lasaloci…

1
Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal ... 19:28

3M ago19:28

19:28

In this week's episode we’ll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies. Featured Articles: Approaching Hyperca…

1
Review Series on a Quarter Century of TKIs in CML 33:05

3M ago33:05

33:05

In this Review Series episode Reflections on a Quarter Century of TKIs in CML introduced by Associate Editor Dr. Jason Gottlieb, we’ll hear from contributing authors Drs. Brian Drucker, Francois Guillot, Tim Hughes and Michael Deininger, as they discuss how CML treatment has been impacted since the introduction of tyrosine kinase inhibitors 25 year…

1
A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes 19:09

3M ago19:09

19:09

In this week's episode, we'll hear about a “belt and suspenders” approach to paroxysmal nocturnal hemoglobinuria, or PNH. We’ll review long-term efficacy data for danicopan—an oral complement factor D inhibitor recently approved as an add-on to C5 inhibitor therapy. After that: researchers show how oral pathogens may exacerbate chronic graft-versus…

1
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer 45:08

3M ago45:08

45:08

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical p…

1
My Journey from Silence to Self-Advocacy 36:17

3M ago36:17

36:17

Join host Talaya Dendy on Navigating Cancer TOGETHER as she shares her powerful and personal story of facing Hodgkin's lymphoma and how it shaped her journey of self-discovery and advocacy. Learn actionable self-advocacy tips, understand the importance of documenting your health, and get inspired to take charge of your own medical journey. Plus, fi…

1
Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells 23:14

4M ago23:14

23:14

In this week's episode we’ll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells. Feature…

1
Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor 31:38

4M ago31:38

31:38

In this Review Series episode on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor introduced by Dr. Thomas Ortel, we’ll hear from contributing authors Drs. Ben Samuelson Jones, Mac Monroe and Peter Lenting as they discuss how the functional roles of these 3 proteins are interconnected. Click here to view the complete…

1
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting 20:01

4M ago20:01

20:01

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including: Early results with teclistamab combined with anti-CD38 therapy Real-world data with teclistamab including its use aft…

1
Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor 18:41

4M ago18:41

18:41

In this week's episode we'll learn about asciminib plus dasatinib in Philadelphia chromosome-positive acute leukemia. In a phase 1 study, combining two tyrosine kinase inhibitors with distinct mechanisms of action had encouraging activity in patients with de novo disease. After that: new research demonstrates that the iron exporter ferroportin cont…

1
Healing with Sound: Dr. Susan James Hegemeyer Explains 29:46

4M ago29:46

29:46

Join Talaya Dendy on Navigating Cancer TOGETHER as she welcomes Dr. Susan E. James Hegemeyer. Discover the various benefits of sound therapy, including pain management, stress reduction, and immune support. Dr. Susan shares her extensive research and personal experiences, highlighting how sound can be a powerful tool for holistic well-being and hea…

1
First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia 20:37

4M ago20:37

20:37

In this week's episode we’ll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia. Featured Articles…

1
Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex 19:02

4M ago19:02

19:02

In this week's episode we'll learn about C3-targeted therapy in autoimmune hemolytic anemias. Based on results of an open-label, phase 2 study, pegcetacoplan was well-tolerated, with encouraging efficacy, particularly in patients with cold agglutinin disease. After that: Venetoclax sensitivity testing to predict AML response. In a significant step …

1
Review Series on Globin Disorders 23:17

4M ago23:17

23:17

In this Review Series episode on Globin Disorders introduced by Drs. Thomas Coates and Irene Roberts, we’ll hear from Dr. Douglas Higgs and Dr. Mitchell Weiss as they address advances in our understanding of globin gene biology. Click here to view the complete Review Series featured in Volume 144 Issue 8 of Blood.…

1
I Believe In Miracles Part 3 with The CROC Podcast 29:15

4M ago29:15

29:15

In this special crossover episode of Navigating Cancer TOGETHER, host Talaya introduces a segment from The CROC Podcast, where Dr. Thomas Eanelli, along with co-host Angel Santana, dives into inspiring stories of cancer survivors. Talaya shares the miraculous journey of Kelly, who was diagnosed with head and neck cancer in 2014 and given only six m…

1
Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell ... 21:35

4M ago21:35

21:35

In this week's episode we’ll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte ant…

1
Explore the Art of Healing Cancer 9:50

5M ago9:50

9:50

Join us for an empowering episode of Navigating Cancer TOGETHER, where we introduce The Art of Healing Cancer Summit. Learn about integrating natural healing with conventional treatments from over 40 experts. This summit, taking place January 21-25, 2025, provides valuable insights on holistic nutrition, mind-body connection, emotional resilience i…

1
Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk 17:20

5M ago17:20

17:20

In this week's episode we'll learn about the role of iron in myelodysplastic syndromes, or MDS. After that: long-term treatment outcomes in immune thrombocytopenia from the STOPAGO study. Finally, new insights into APL treatment outcomes and prognostic factors from the large-scale Harmony APL project which used ATRA-Arsenic combination therapy. Fea…

1
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer 36:04

5M ago36:04

36:04

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium: Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast ca…

1
Tim Sohn's Perspective on Living with Chronic Myeloid Leukemia 42:36

5M ago42:36

42:36

Join host Talaya Dendy on Navigating Cancer TOGETHER as she welcomes Tim Sohn, an 18-year chronic myeloid leukemia (CML) survivor. Tim shares his personal journey, the importance of community building, his involvement in the #SpeakUpCML campaign, and the impact of living with an invisible illness. Don't miss this inspiring conversation filled with …

1
Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment 20:19

5M ago20:19

20:19

In this week's episode, we’ll learn about the prevalence and impact of dexamethasone dose reductions during triple or quadruple therapy for newly diagnosed multiple myeloma, a conditional knockout mouse model for testing gene therapy in X-linked sideroblastic anemia, and real-world efficacy and safety of ciltacabtagene autoleucel in patients with r…

1
Finding Inner Peace During Cancer: How to Accept Difficult Emotions with Amanda Curry 48:14

5M ago48:14

48:14

In this episode of Navigating Cancer TOGETHER, hosted by Talaya Dendy, special guest Amanda Curry—a trauma-informed Doctor of Physical Therapy and Certified Oncology Specialist—shares her invaluable experiences and insights from her work in pediatric oncology. Amanda discusses the emotional challenges faced by both children with cancer and their pa…

1
Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax 19:01

5M ago19:01

19:01

In this week's episode, we'll be comparing BTK inhibitors in relapsed/refractory CLL. Then, we'll hear how researchers in the UK unraveled the genetic background of the AnWj blood group. Finally we'll learn about the role of BCL-2 and BAFF in CLL cell survival following venetoclax therapy. Featured Articles: Deletions in the MAL gene result in loss…

Podcasts Worth a Listen

Chronic Myeloid Leukemia Podcasts

Podcasts Worth a Listen

Quick Reference Guide